Human Papillomavirus (HPV) causes 99.7% of cervical cancers, a leading cause of cancer among Indian women.
HPV vaccines prevent HPV-related cancers by stimulating the immune system to produce antibodies.
Details
HPV vaccines recommended for children aged 9 to 13 years or those at high risk.
Four types of HPV vaccines authorised in India, including Cervarix and Gardasil.
Vaccination reduces incidence and mortality of cervical cancer, the second most common cancer in India.
States like Arunachal Pradesh have the highest incidence rates of cervical cancer.
Challenges
High cost: Vaccines priced between ₹2,000 and ₹10,850 per dose.
Awareness barriers: Lack of understanding about HPV’s benefits and stigma around reproductive health.
Limited access: Vaccines available only in private healthcare setups, with NTAGI recommending inclusion in the national immunisation programme.
Implications
Inclusion of HPV vaccines in national immunisation could significantly reduce cervical cancer rates.
Awareness campaigns are critical for addressing safety concerns and cultural biases.
Expanding access can protect vulnerable populations, especially in rural areas.
COMMENTS